7764-95-6

Basic information

• Product Name: BOC-D-Alanine
• Synonyms: BOC-D-ALANINE;BOC-D-ALANINE-OH;BOC-D-ALA-OH;BOC-D-ALA;T-BUTYLOXYCARBONYL-D-ALANINE;N-ALPHA-TERT-BUTYLOXYCARBONYL-D-ALANINE;N-ALPHA-T-BUTOXYCARBONYL-D-ALANINE;N-ALPHA-T-BOC-D-ALA
• CAS NO: 7764-95-6
• Molecular Formula: C₈H₁₅NO₄
• Molecular Weight: 189.21
• EINECS: 1533716-785-6
• Product Categories: Protected Amino Acids;pharmacetical;Amino Acids;Alanine [Ala, A];Boc-Amino Acids and Derivative;Amino Acids (N-Protected);Biochemistry;Boc-Amino Acids;Boc-Amino acid series
• Mol File: 7764-95-6.mol

Chemical Properties

• Melting Point: 81-84 °C
• Boiling Point: 324.46°C (rough estimate)
• Flash Point: 147.9 °C
• Appearance: White/Powder
• Density: 1.2321 (rough estimate)
• Vapor Pressure: 6.39E-05mmHg at 25°C
• Refractive Index: 26 ° (C=2, AcOH)
• Storage Temp.: -20°C
• Solubility: Chloroform, DMSO, Methanol
• PKA: 4.02±0.10(Predicted)
• BRN: 2048396
• CAS DataBase Reference: BOC-D-Alanine(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-D-Alanine(7764-95-6)
• EPA Substance Registry System: BOC-D-Alanine(7764-95-6)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38
• Safety Statements: 24/25-36-26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 7764-95-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BOC-D-Alanine is used as a building block for the synthesis of various pharmaceutical compounds due to its unique properties as an amino acid. It plays a crucial role in the development of new drugs targeting bacterial cell wall biosynthesis and potentially in the treatment of brain tumors.
Used in Bacterial Cell Wall Research:
BOC-D-Alanine is used as a research compound for studying the biosynthesis of peptidoglycan crosslinking sub-units in bacterial cell walls. Understanding the role of D-Alanine in this process can lead to the development of novel antibiotics that target bacterial cell wall synthesis.
Used in Anticancer Research:
BOC-D-Alanine is used as a research compound in the field of anticancer drug development, particularly for brain tumors. Its cytotoxic oxidative stress properties make it a promising candidate for further investigation into its potential therapeutic applications in cancer treatment.

InChI:InChI=1/C8H15NO4/c1-5(6(10)11)9-7(12)13-8(2,3)4/h5H,1-4H3,(H,9,12)(H,10,11)/p-1/t5-/m1/s1

Upstream product

• 13303-10-1 tert-Butyl 4-nitrophenyl carbonate 
• 302-72-7 rac-Ala-OH 
• 75-65-0 tert-butyl alcohol 
• 68992-59-6 C₁₁H₁₉NO₆ 
• 57022-34-1 tert-butyl cyanoformate 
• 147252-84-4 tert-butyl (1-hydroxypropan-2-yl)carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 4530-20-5 BOC-glycine 
• 74-88-4 methyl iodide 
• 75-44-5 phosgene 
• 108811-48-9 tert-butyl (tert-butoxycarbonyl)alaninate 
• 909114-65-4 tert-butyl 4,6-dimethoxy-1,3,5-triazinyl carbonate 
• 117681-86-4 (1R,2S,5R)-2-(1-methyl-1-phenylethyl)-5-methylcyclohexyl (tert-butoxycarbonyl)aminoacetate 
• 117049-10-2 2-tert-Butoxycarbonylamino-propionic acid (1R,2S,5R)-5-methyl-2-(1-methyl-1-phenyl-ethyl)-cyclohexyl ester 

Downstream Products

• 16561-96-9 N-tert-butoxycarbonyl-DL-alanine (SR)-3-oxo-2-trityl-isoxazolidin-4-ylamide 
• 16561-96-9 N-tert-butoxycarbonyl-DL-alanine (RS)-3-oxo-2-trityl-isoxazolidin-4-ylamide 
• 101015-33-2 N--N,N'-dicyclohexyl-harnstoff 
• 117049-10-2 (1R,2S,5R)-2-(1-methyl-1-phenylethyl)-5-methylcyclohexyl (S)-2-<(tert-butoxycarbonyl)amino>propanoate 
• 135214-55-0 Boc-DL-Ala-DL-Ala-OBzl 
• 135112-44-6 Boc-DL-Ala-DL-Ala-DL-Ala-OBzl 
• 158461-97-3 {1-[2-Pyridin-2-yl-5-(2,2,2-trifluoro-ethoxy)-phenylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 119289-82-6 {1-[2-Pyridin-3-yl-5-(2,2,2-trifluoro-ethoxy)-phenylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 3744-87-4 Boc-(R)-Ala 
• 51814-53-0 N-tert-butoxycarbonyl-L-alanine ethyl ester 
• 86194-94-7 (2-Imidazol-1-yl-1-methyl-2-oxo-ethyl)-carbamic acid tert-butyl ester 
• 220903-51-5 <(tert-butyloxycarbonyl)amino>-N-(4-methoxyphenyl)propanamide 
• 220903-71-9 N-<4-phenyl>-2-(tert-butyloxycarbonylamino)propanamide 
• 141041-80-7 N-(tert-Butyloxycarbonyl)-DL-alaninnitril 

Relevant articles and documents

SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME

Disclosed are compounds, and pharmaceutically acceptable salts thereof, that can ameliorate or treat a viral infection in a subject in need thereof. The disclosure also includes conjugates of such compounds with a protease.

Highly Stable Zr(IV)-Based Metal-Organic Frameworks for Chiral Separation in Reversed-Phase Liquid Chromatography

Separation of racemic mixtures is of great importance and interest in chemistry and pharmacology. Porous materials including metal-organic frameworks (MOFs) have been widely explored as chiral stationary phases (CSPs) in chiral resolution. However, it remains a challenge to develop new CSPs for reversed-phase high-performance liquid chromatography (RP-HPLC), which is the most popular chromatographic mode and accounts for over 90% of all separations. Here we demonstrated for the first time that highly stable Zr-based MOFs can be efficient CSPs for RP-HPLC. By elaborately designing and synthesizing three tetracarboxylate ligands of enantiopure 1,1′-biphenyl-20-crown-6, we prepared three chiral porous Zr(IV)-MOFs with the framework formula [Zr6O4(OH)8(H2O)4(L)2]. They share the same flu topological structure but channels of different sizes and display excellent tolerance to water, acid, and base. Chiral crown ether moieties are periodically aligned within the framework channels, allowing for stereoselective recognition of guest molecules via supramolecular interactions. Under acidic aqueous eluent conditions, the Zr-MOF-packed HPLC columns provide high resolution, selectivity, and durability for the separation of a variety of model racemates, including unprotected and protected amino acids and N-containing drugs, which are comparable to or even superior to several commercial chiral columns for HPLC separation. DFT calculations suggest that the Zr-MOF provides a confined microenvironment for chiral crown ethers that dictates the separation selectivity.

PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF

The invention provides a peptide amide compound represented by the general general formula (I), a preparation method thereof, and a medical application thereof. The compound has a novel structure, better biological activity, and better analgesic effect.

Cytotoxic activity of synthetic chiral amino acid derivatives

Cancer is a chronic degenerative disease considered one of the most important causes of death worldwide. In this context, a series of dual-protected amino acid derivatives was synthesized and evaluated as potential novel anticancer agents. The 40 derivatives were prepared in up to three reaction steps. The cytotoxic activities were screened in vitro against a panel of tumor and non-tumor cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Among the synthesized derivatives, three of them showed promising activity against cancer cells with half-maximal inhibitory concentration (IC50) ranging between 1.7-6.1 μM. The most promising derivative, bearing both a lipophilic N-alkyl diamine moiety and a protected amino acid scaffold showed a selectivity index of 3.4 towards tumor cells. The N-alkyl diamine moiety seems to play a crucial role in the enhancement of the anticancer activity. On the other hand, the incorporation of an amino acid scaffold resulted in increase in the selectivity towards cancer cell lines.

GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF

Provided are a glucopyranosyl derivative as a sodium-dependent glucose transporters inhibitor, especially as a SGLT1 inhibitor, a pharmaceutically acceptable salt or a stereoisomer thereof, a pharmaceutical composition thereof, and the uses of the compound and pharmaceutical composition thereof in the preparation of drugs for the treatment of diabetes and diabetes-related diseases.

Alanine derivative and preparation method and application thereof

The invention discloses an alanine derivative and a preparation method and application thereof. The preparation comprises the following steps: taking biphenylpyridine as a hinge region binding fragment, introducing L-alanine as a flexible linker by adopting a fragment drug design strategy to construct a compound library with kinase inhibitory activity, and discovering a tyrosine kinase inhibitor with Bcr-Abl kinase inhibitory activity through ADP-Glo kinase activity screening. The compound can be used for preparing anti-tumor (chronic myelogenous leukemia) drugs, inhibits kinase activity of Bcr-Abl and Bcr-AblT315I, and has the activity of inhibiting cell proliferation of K562 cells. The introduction of an alanine structure has an important effect on the inhibitory activity of the compound, the structural diversity of the kinase inhibitor can be expanded, and the activity result shows that the structure can be used as a Linker pharmacodynamic fragment of the Bcr-Abl tyrosine kinase inhibitor.

INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN

Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.

Mandelic acid aminoacid aminopeptidase N inhibitor and synthesis method

The invention relates to a mandelic acid aminoacid aminopeptidase N inhibitor, the general chemical formula of which is in the drawing (The formula is shown in the description.), wherein R1, R2, R3 and R4 are H, F, Cl, Br, NO2, OCH3, CH3 or CH(CH3)3; and R5 is CH3 or CH2CH(CH3)2. Thiosemicarbazide and substituted benzoic acid are utilized to carry out condensation reaction, so that a substituted phenylthiadiazole derivative is produced, the substituted phenylthiadiazole derivative is connected with Boc-protected amino acid by acylation reaction, the protecting group is then removed under the effect of strong acid, and finally, after acylation with trimethylsiloxylphenylacetyl chloride, the target compound is obtained. The route of the synthesis process is short, the raw materials are easyto obtain, and the production cost is low.

Synthesis and molecular simulation study of furoic peptidomimetic derivatives as potent aminopeptodase N inhibitors

The aminopeptidase N (APN) plays a critical role in angiogenesis and is over-expressed in tumor cells. In this paper, we report the synthesis and enzyme inhibition assay of furoic peptidomimetic compounds. These new compounds exhibit potent inhibitory ability toward APN with IC50 values lying in the micromolar level. The binding mode of inhibitors in APN active site was explained by a molecular simulation study. These data reveal that ligand coordinating with the catalytic Zn-ion is very important for inhibitory activities.

Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicines

The present invention relates to an amine compound for inhibiting SSAO/VAP-1 and application thereof in medicines. In particular, the present invention relates to an amine compound for inhibiting a semicarbazide-sensitive oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, or a pharmaceutically acceptable salt thereof, a stereoisomer or an/a E/Z isomer, further relates to a pharmaceutical composition containing the amine compound. The invention further relates to the application of the amine compound and the pharmaceutical composition in manufacture of the medicines for treatment of inflammation, inflammation-related diseases and immune diseases.